Clinical pharmacokinetics and pharmacodynamics of oral systemic nonbiologic therapies for psoriasis patients

References

• Armstrong A, Mehta M, Schupp C, et al. Psoriasis prevalence in adults in the United States. JAMA Dermatol. 2021;157(8):940–946. doi: 10.1001/jamadermatol.2021.2007
   PubMed Web of Science ®Google Scholar
• Zhou X, Chen Y, Cui L, et al. Advances in the pathogenesis of psoriasis: from keratinocyte perspective. Cell Death Dis. 2022;13(1):1–13. doi: 10.1038/s41419-022-04523-3
   Web of Science ®Google Scholar
• Kimmel GW, Lebwohl M. Psoriasis: overview and diagnosis. Evid-Based Psoriasis. 2018;1–16.
   Google Scholar
• Hendriks AGM, Keijsers RRMC, de Jong EMGJ, et al. Efficacy and safety of combinations of first-line topical treatments in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol JEADV. 2013;27(8):931–951. doi: 10.1111/jdv.12058
   PubMed Web of Science ®Google Scholar
• Balak DMW. First-line systemic treatment of psoriasis: staying conventional or going biologic? Br J Dermatol. 2017;177(4):897–898. doi: 10.1111/bjd.15885
   PubMed Web of Science ®Google Scholar
• Hsieh T, Tsai T. Combination of methotrexate with oral disease-modifying antirheumatic drugs in psoriatic arthritis: a systematic review. Immunotherapy. 2024;16(2):115–130. doi: 10.2217/imt-2023-0139
   PubMed Web of Science ®Google Scholar
• Bath RK, Brar NK, Forouhar FA, et al. A review of methotrexate-associated hepatotoxicity. J Dig Dis. 2014;15:517–524. doi: 10.1111/1751-2980.12184
   PubMed Web of Science ®Google Scholar
• Markham T, Watson A, Rogers S. Adverse effects with long-term cyclosporin for severe psoriasis: adverse effects of long-term cyclosporin. Clin Exp Dermatol. 2002;27(2):111–114. doi: 10.1046/j.1365-2230.2002.00998.x
   PubMed Web of Science ®Google Scholar
• Dogra S, Krishna V, Kanwar AJ. Efficacy and safety of systemic methotrexate in two fixed doses of 10 mg or 25 mg orally once weekly in adult patients with severe plaque-type psoriasis: a prospective, randomized, double-blind, dose-ranging study: methotrexate in psoriasis. Clin Exp Dermatol. 2012;37(7):729–734. doi: 10.1111/j.1365-2230.2012.04440.x
   PubMed Web of Science ®Google Scholar
• Radmanesh M, Rafiei B, Moosavi Z, et al. Weekly vs. daily administration of oral methotrexate (MTX) for generalized plaque psoriasis: a randomized controlled clinical trial. Int J Dermatol. 2011;50(10):1291–1293. doi: 10.1111/j.1365-4632.2011.04967.x
   PubMed Web of Science ®Google Scholar
• Jensen P, Skov L. Psoriasis and obesity. Dermatology. 2016;232(6):633–639. doi: 10.1159/000455840
   PubMed Web of Science ®Google Scholar
• Hutmacher M, Papp K, Krishnaswami S, et al. Evaluating dosage optimality for tofacitinib, an Oral Janus Kinase Inhibitor, in plaque psoriasis, and the influence of body weight. CPT: Pharmacomet Syst Pharmacol. 2017;6:322–330. doi: 10.1002/psp4.12182
   PubMedGoogle Scholar
• Guenther LC, Kunynetz R, Lynde CW, et al. Acitretin use in dermatology. J Cutan Med Surg. 2017;21(3_suppl):2S–12S. doi: 10.1177/1203475417733414
   PubMedGoogle Scholar
• Pilkington T, Brogden RN. Acitretin: a review of its pharmacology and therapeutic use. Drugs. 1992;43(4):597–627. doi: 10.2165/00003495-199243040-00010
   Web of Science ®Google Scholar
• LeMotte P, Keidel 2S, Apfel C. Characterization of synthetic retinoids with selectivity for retinoic acid or retinoid X nuclear receptors. Biochim Biophys Acta. 1996;1289:298–304. doi: 10.1016/0304-4165(95)00179-4
   PubMed Web of Science ®Google Scholar
• Carretero G, Ribera M, Belinchón I, et al. Guidelines for the use of acitretin in psoriasis. Psoriasis Group of the Spanish Academy of Dermatology and venereology. Actas Dermosifiliogr. 2013;104:598–616. doi: 10.1016/j.ad.2013.01.003
   PubMedGoogle Scholar
• Diaz BV, Lenoir M-C, Ladoux A, et al. Regulation of Vascular Endothelial Growth Factor Expression in human keratinocytes by retinoids*. J Biol Chem. 2000;275(1):642–650. doi: 10.1074/jbc.275.1.642
   PubMed Web of Science ®Google Scholar
• Cai A, Liu N, Lin Z, et al. In vitro effects of acitretin on human neuronal SH-SY5Y cells. Neurochem Res. 2023;48(1):72–81. doi: 10.1007/s11064-022-03716-8
   PubMed Web of Science ®Google Scholar
• Niu X, Cao W, Ma H, et al. Acitretin exerted a greater influence on T-helper (Th)1 and Th17 than on Th2 cells in treatment of psoriasis vulgaris. J Dermatol. 2012;39(11):916–921. doi: 10.1111/j.1346-8138.2012.01637.x
   PubMed Web of Science ®Google Scholar
• Sarkar R, Chugh S, Garg V. Acitretin in dermatology. Indian J Dermatol Venereol Leprol. 2013;79(6):759. doi: 10.4103/0378-6323.120721
   PubMed Web of Science ®Google Scholar
• PubChem. Acitretin [Internet]. [cited 2024 Jan 25]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/5284513
   Google Scholar
• Lee CS, Li K. A review of acitretin for the treatment of psoriasis. Expert Opin Drug Saf. 2009;8(6):769–779. doi: 10.1517/14740330903393732
   PubMed Web of Science ®Google Scholar
• Ghasri P, Yentzer BA, Dabade TS, et al. Acitretin for the treatment of psoriasis: an assessment of national trends. J Drugs Dermatol JDD. 2011;10:873–877.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Drake L, Menter A, et al. Consensus conference: acitretin in combination with UVB or PUVA in the treatment of psoriasis. J Am Acad Dermatol. 2001;45:544–553. doi: 10.1067/mjd.2001.116347
   PubMed Web of Science ®Google Scholar
• Ruzicka T, Sommerburg C, Braun-Falco O, et al. Efficiency of acitretin in combination with UV-B in the treatment of severe psoriasis. Arch dermatol. 1990;126:482–486. doi: 10.1001/archderm.1990.01670280066012
   PubMed Web of Science ®Google Scholar
• Arora S, Das P, Arora G. Systematic review and recommendations to combine newer therapies with conventional therapy in psoriatic disease. Front Med. 2021;19:696597. doi: 10.3389/fmed.2021.696597
   Google Scholar
• Tanew A, Guggenbichler A, Hönigsmann H, et al. Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study. J Am Acad Dermatol. 1991;25(4):682–684. doi: 10.1016/0190-9622(91)70253-X
   PubMed Web of Science ®Google Scholar
• Pearce DJ, Klinger S, Ziel KK, et al. Low-dose acitretin is associated with fewer adverse events than high-dose acitretin in the treatment of psoriasis. Arch Dermatol. 2006;142(8):1000–1004. doi: 10.1001/archderm.142.8.1000
   PubMedGoogle Scholar
• Bangsgaard N, Rørbye C, Skov L. Treating psoriasis during pregnancy: safety and efficacy of treatments. Am J Clin Dermatol. 2015;16(5):389–398. doi: 10.1007/s40257-015-0137-5
   PubMed Web of Science ®Google Scholar
• Drugs and Lactation database (LactMed®). National Institute of Child Health and Human Development. 2006. [cited 2023 Dec 24]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK501922/
   Google Scholar
• Sadowska M, Narbutt J, Skibińska M, et al. Pros and cons of using systemic acitretin in the paediatric population. Adv Dermatol Allergol Dermatol Alergol. 2022;39:34–38. doi: 10.5114/ada.2020.98558
   PubMed Web of Science ®Google Scholar
• Chan ESL, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. Arthritis Research. 2002;4:266–273. doi: 10.1186/ar419
   PubMedGoogle Scholar
• Menter A, Gelfand JM, Connor C, et al. Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020;82(6):1445–1486. doi: 10.1016/j.jaad.2020.02.044
   PubMed Web of Science ®Google Scholar
• Cream JJ, Pole DS. The effect of methotrexate and hydroxyurea on neutrophil chemotaxis. Br J Dermatol. 1980;102(5):557–563. doi: 10.1111/j.1365-2133.1980.tb07655.x
   PubMed Web of Science ®Google Scholar
• Ternowitz T, Herlin T. Neutrophil and monocyte chemotaxis in methotrexate-treated psoriasis patients. Acta Derm Venereol Suppl (Stockh). 1985;120:23–26.
   PubMedGoogle Scholar
• Saporito FC, Menter MA. Methotrexate and psoriasis in the era of new biologic agents. J Am Acad Dermatol. 2004;50(2):301–309. doi: 10.1016/S0190-9622(03)00803-X
   PubMed Web of Science ®Google Scholar
• Jeffes EWB, McCullough JL, Pittelkow MR, et al. Methotrexate therapy of psoriasis: differential sensitivity of proliferating lymphoid and epithelial cells to the Cytotoxic and growth-inhibitory effects of methotrexate. J Invest Dermatol. 1995;104(2):183–188. doi: 10.1111/1523-1747.ep12612745
   PubMed Web of Science ®Google Scholar
• Genestier L, Paillot R, Fournel S, et al. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest. 1998;102(2):322–328. doi: 10.1172/JCI2676
   PubMed Web of Science ®Google Scholar
• Weinstein GD, Goldfaden G, Frost P. Methotrexate: mechanism of action on DNA synthesis in psoriasis. Arch Dermatol. 1971;104:236–243. doi: 10.1001/archderm.1971.04000210010003
   PubMed Web of Science ®Google Scholar
• Grim J, Chl?dek J, Mart?nkov? J. Pharmacokinetics and pharmacodynamics of methotrexate in Non-Neoplastic diseases. Clin Pharmacokinet. 2003;42:139–151. doi: 10.2165/00003088-200342020-00003
   PubMed Web of Science ®Google Scholar
• Oguey D, Kölliker F, Gerber NJ, et al. Effect of food on the bioavailability of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 1992;35(6):611–614. doi: 10.1002/art.1780350603
   PubMed Web of Science ®Google Scholar
• Vena G, Cassano N, Iannone F. Update on subcutaneous methotrexate for inflammatory arthritis and psoriasis. Ther Clin Risk Manag. 2018;9:105–116. doi: 10.2147/TCRM.S154745
   Google Scholar
• Brooks PJ, Spruill WJ, Parish RC, et al. Pharmacokinetics of methotrexate administered by intramuscular and subcutaneous injections in patients with rheumatoid arthritis. Arthritis Rheum. 1990;33(1):91–94. doi: 10.1002/art.1780330112
   PubMedGoogle Scholar
• Jundt JW, Browne BA, Fiocco GP, et al. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol. 1993;20:1845–1849.
   PubMed Web of Science ®Google Scholar
• Attwa E, Elkot R, Abdelshafey A, et al. Subcutaneous methotrexate versus oral form for the treatment and prophylaxis of chronic plaque psoriasis. Dermatol Ther. 2019;32(5):e13051. doi: 10.1111/dth.13051
   PubMed Web of Science ®Google Scholar
• Choonhakarn C, Chaowattanapanit S, Julanon N, et al. Comparison of the clinical efficacy of subcutaneous vs. oral administration of methotrexate in patients with psoriasis vulgaris: a randomized controlled trial. Clin Exp Dermatol. 2022;47(5):942–948. doi: 10.1111/ced.15102
   PubMed Web of Science ®Google Scholar
• Dogra S, Singh N, Kumar S, et al. Comparison of overall efficacy and safety of oral versus subcutaneous methotrexate in severe psoriasis. Dermatol Ther. 2022;35(8):e15656. doi: 10.1111/dth.15656
   PubMed Web of Science ®Google Scholar
• van Ede AE, Laan RFJM, Blom HJ, et al. Methotrexate in rheumatoid arthritis: an updatewith focus on mechanisms involved in toxicity. Semin Arthritis Rheum. 1998;27:277–292. doi: 10.1016/S0049-0172(98)80049-8
   PubMed Web of Science ®Google Scholar
• Bjerring P, Beck H, Zachariae H, et al. Topical treatment of psoriatic skin with methotrexate cream: a clinical, pharmacokinetic, and histological study. Acta Derm Venereol. 1986;66(6):515–519. doi: 10.2340/0001555566515519
   PubMed Web of Science ®Google Scholar
• Hendel J, Nyfors A. Impact of methotrexate therapy on the folate status of psoriatic patients. Clin Exp Dermatol. 1985;10(1):30–35. doi: 10.1111/j.1365-2230.1985.tb02548.x
   PubMed Web of Science ®Google Scholar
• Seideman P, Beck O, Eksborg S, et al. The pharmacokinetics of methotrexate and its 7‐hydroxy metabolite in patients with rheumatoid arthritis. Br J Clin Pharmacol. 1993;35(4):409–412. doi: 10.1111/j.1365-2125.1993.tb04158.x
   PubMed Web of Science ®Google Scholar
• Godfrey C, Sweeney K, Miller K, et al. The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis. Br J Clin Pharmacol. 1998;46(4):369–376. doi: 10.1046/j.1365-2125.1998.t01-1-00790.x
   PubMed Web of Science ®Google Scholar
• Grozdev IS, Van Voorhees AS, Gottlieb AB, et al. Psoriasis in the elderly: from the medical board of the national psoriasis foundation. J Am Acad Dermatol. 2011;65(3):537–545. doi: 10.1016/j.jaad.2010.05.014
   PubMed Web of Science ®Google Scholar
• Kalb RE, Strober B, Weinstein G, et al. Methotrexate and psoriasis: 2009 national psoriasis foundation consensus conference. J Am Acad Dermatol. 2009;60:824–837. doi: 10.1016/j.jaad.2008.11.906
   PubMed Web of Science ®Google Scholar
• Hendel J, Nyfors A. Pharmacokinetics of methotrexate in erythrocytes in psoriasis. Eur J Clin Pharmacol. 1984;27(5):607–610. doi: 10.1007/BF00556900
   PubMed Web of Science ®Google Scholar
• Olsen EA. The pharmacology of methotrexate. J Am Acad Dermatol. 1991;25(2):306–318. doi: 10.1016/0190-9622(91)70199-C
   PubMed Web of Science ®Google Scholar
• West J, Ogston S, Foerster J. Safety and efficacy of methotrexate in psoriasis: a meta-analysis of published trials. Chopra A, editor. PloS One. 2016;11:e0153740. doi: 10.1371/journal.pone.0153740
   PubMedGoogle Scholar
• Saurat J-H, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION): adalimumab vs. methotrexate in psoriasis. Br J Dermatol. 2007;158(3):558–566. doi: 10.1111/j.1365-2133.2007.08315.x
   PubMed Web of Science ®Google Scholar
• Sbidian E, Chaimani A, Guelimi R, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis. Cochrane Database Syst Rev [Internet]. 2023 [cited 2024 Jan 24]; 2023(7). doi: 10.1002/14651858.CD011535.pub6
   Google Scholar
• Barker J, Hoffmann M, Wozel G, et al. Efficacy and safety of infliximab vs. methotrexate in patients with moderate‐to‐severe plaque psoriasis: results of an open‐label, active‐controlled, randomized trial (RESTORE1). Br J Dermatol. 2011;165(5):1109–1117. doi: 10.1111/j.1365-2133.2011.10615.x
   PubMed Web of Science ®Google Scholar
• Jabbar-Lopez ZK, Yiu ZZN, Ward V, et al. Quantitative evaluation of biologic therapy options for psoriasis: a systematic review and network meta-analysis. J Invest Dermatol. 2017;137(8):1646–1654. doi: 10.1016/j.jid.2017.04.009
   PubMed Web of Science ®Google Scholar
• Rosmarin DM, Lebwohl M, Elewski BE, et al. Cyclosporine and psoriasis: 2008 national psoriasis foundation consensus conference. J Am Acad Dermatol. 2010;62:838–853. doi: 10.1016/j.jaad.2009.05.017
   PubMed Web of Science ®Google Scholar
• Haider AS, Lowes MA, Suarez- FarinFarinas M, et al. Identification of cellular pathways of “type 1,” Th17 T cells, and TNF- and Inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacogenomic study of cyclosporine a in Psoriasis1. J Immunol. 2008;180(3):1913–1920. doi: 10.4049/jimmunol.180.3.1913
   PubMed Web of Science ®Google Scholar
• Faulds D, Goa KL, Benfield P. Cyclosporin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs. 1993;45:953–1040. doi: 10.2165/00003495-199345060-00007
   PubMed Web of Science ®Google Scholar
• Maza A, Montaudié H, Sbidian E, et al. Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis. J Eur Acad Dermatol Venereol. 2011;25(s2):19–27. doi: 10.1111/j.1468-3083.2011.03992.x
   PubMedGoogle Scholar
• Ho VCY, Griffiths CEM, Berth-Jones J, et al. Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study. J Am Acad Dermatol. 2001;44(4):643–651. doi: 10.1067/mjd.2001.112400
   PubMed Web of Science ®Google Scholar
• Shupack J, Drake L, Levine N, et al. Cyclosporine as maintenance therapy in patients with severe psoriasis. J Am Acad Dermatol. 1997;36(3):423–432. doi: 10.1016/S0190-9622(97)80219-8
   PubMed Web of Science ®Google Scholar
• Berth‐Jones J. The use of ciclosporin in psoriasis. J Dermatol Treat. 2005;16(5–6):258–277. doi: 10.1080/09546630500423914
   PubMed Web of Science ®Google Scholar
• Soleymani T, Vassantachart JM, Wu JJ. Comparison of guidelines for the use of cyclosporine for psoriasis: a critical appraisal and comprehensive review. J Drugs Dermatol. 2016;15:293–301.
   PubMed Web of Science ®Google Scholar
• Ramirez-Fort MK, Levin AA, Au S, et al. Continuous versus intermittent therapy for moderate-to-severe psoriasis. Clin Exp Rheumatol. 2013;31:S63–70.
   PubMed Web of Science ®Google Scholar
• Chaidemenos G, Mourellou O, Avgoustinaki N, et al. Intermittent vs. continuous 1-year cyclosporin use in chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2007;21(9):1203–1208. doi: 10.1111/j.1468-3083.2007.02226.x
   PubMed Web of Science ®Google Scholar
• Ohtsuki M, Nakagawa H, Sugai J, et al. Long-term continuous versus intermittent cyclosporin: therapy for psoriasis. J Dermatol. 2003;30(4):290–298. doi: 10.1111/j.1346-8138.2003.tb00390.x
   PubMed Web of Science ®Google Scholar
• Schafer PH, Chen P, Fang L, et al. The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase III, randomized, placebo-controlled trial (PALACE 1). J Immunol Res. 2015;2015:1–10. doi: 10.1155/2015/906349
   Web of Science ®Google Scholar
• Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (efficacy and safety trial evaluating the effects of apremilast in psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73(1):37–49. doi: 10.1016/j.jaad.2015.03.049
   PubMed Web of Science ®Google Scholar
• Pincelli C, Schafer PH, French LE, et al. Mechanisms underlying the clinical effects of apremilast for psoriasis. J Drugs Dermatol. 2018;17:835–840.
   PubMed Web of Science ®Google Scholar
• Imafuku S, Nemoto O, Okubo Y, et al. Pharmacodynamic analysis of apremilast in Japanese patients with moderate to severe psoriasis: results from a phase 2b randomized trial. J Dermatol. 2021;48(1):80–84. doi: 10.1111/1346-8138.15596
   PubMed Web of Science ®Google Scholar
• Strober B, Alikhan A, Lockshin B, et al. Apremilast mechanism of efficacy in systemic-naive patients with moderate plaque psoriasis: pharmacodynamic results from the UNVEIL study. J Dermatol Sci. 2019;96(3):126–133. doi: 10.1016/j.jdermsci.2019.09.003
   PubMed Web of Science ®Google Scholar
• Medvedeva IV, Stokes ME, Eisinger D, et al. Large-scale analyses of disease biomarkers and apremilast pharmacodynamic effects. Sci Rep. 2020;10:p. 605.
   Google Scholar
• Paller AS, Hong Y, Becker EM, et al. Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: results from a phase 2 open-label study. J Am Acad Dermatol. 2020;82(2):389–397. doi: 10.1016/j.jaad.2019.08.019
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kumar G, Schafer P, et al. Disposition, metabolism and mass balance of [14 C]apremilast following oral administration. Xenobiotica. 2011;41(12):1063–1075. doi: 10.3109/00498254.2011.604745
   PubMed Web of Science ®Google Scholar
• Panda G, Sahoo JP, Mohanty P, et al. Apremilast or methotrexate: the arrows in the quiver for psoriasis. Cureus [Internet]. 2023 [cited 2024 Jan 23]; Available from]. Available from: https://www.cureus.com/articles/156907-apremilast-or-methotrexate-the-arrows-in-the-quiver-for-psoriasis
   Web of Science ®Google Scholar
• Reich K, Gooderham M, Green L, et al. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from a phase IIIb, randomized, placebo‐controlled trial (LIBERATE). J Eur Acad Dermatol Venereol. 2017;31(3):507–517. doi: 10.1111/jdv.14015
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2023;88(1):29–39. doi: 10.1016/j.jaad.2022.07.002
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Laurence A, O’Shea JJ. Janus kinases in immune cell signaling. Immunol Rev. 2009;228(1):273–287. doi: 10.1111/j.1600-065X.2008.00754.x
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Gadina MJ. Jakpot! New small molecules in autoimmune and inflammatory diseases. Exp Dermatol. 2014;23(1):7–11. doi: 10.1111/exd.12265
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Weigert C, Röcken M. Immunopathogenesis and role of T cells in psoriasis. Clin Dermatol. 2007;25(6):574–580. doi: 10.1016/j.clindermatol.2007.08.012
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by Tofacitinib (CP-690,550). J Immunol. 2011;186(7):4234–4243. doi: 10.4049/jimmunol.1003668
   PubMed Web of Science ®Google Scholar
• Kurtovic N, Halilovic E. Serum concentrations of interferon gamma (IFN- and #947;) in patients with psoriasis: correlation with clinical type and severity of the disease. Med Arch. 2018;72:410. doi: 10.5455/medarh.2018.72.410-413
   PubMedGoogle Scholar
• Kurtovic N, Halilovic E. Serum levels of tumor necrosis factor - alpha in patients with psoriasis. Mater Socio Medica. 2022;34(1):40. doi: 10.5455/msm.2022.33.40-43
   PubMedGoogle Scholar
• Zaba LC, Cardinale I, Gilleaudeau P, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med. 2007;204(13):3183–3194. doi: 10.1084/jem.20071094
   PubMed Web of Science ®Google Scholar
• Stritesky G, Yeh N, Kaplan M. IL-23 promotes maintenance but not commitment to the Th17 lineage. J Immunol. 2008;181(9):5948–5955. doi: 10.4049/jimmunol.181.9.5948
   PubMed Web of Science ®Google Scholar
• Pfizer. XeljanzTM (tofacitinib) tablets, for oral use: US prescribing information. 2012. Available from: https://labeling.pfizer.com/showlabeling.aspx?id=959.
   Google Scholar
• US Department of Health and Human Services. Clinical Pharmacology And Biopharmaceutics Review(s). Application Number: 203214Orig1s000. 2011. cited 2024 Jan 10.
   Google Scholar
• Riese RJ, Krishnaswami S, Kremer J. Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes. Best Pract Res Clin Rheumatol. 2010;24(4):513–526. doi: 10.1016/j.berh.2010.02.003
   PubMed Web of Science ®Google Scholar
• Hutmacher MM, Krishnaswami S, Kowalski KG. Exposure-response modeling using latent variables for the efficacy of a JAK3 inhibitor administered to rheumatoid arthritis patients. J Pharmacokinet Pharmacodyn. 2008;35(2):139–157. doi: 10.1007/s10928-007-9080-2
   PubMed Web of Science ®Google Scholar
• Gupta P, Chow V, Wang R, et al. Evaluation of the effect of fluconazole and ketoconazole on the pharmacokinetics of tofacitinib in healthy adult subjects. Clin Pharmacol Drug Dev. 2014;3(1):72–77. doi: 10.1002/cpdd.71
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Xeljanz® highlights of prescribing information. 2018 cited 2024 Jan 10.
   Google Scholar
• Krishnaswami S, Boy M, Chow V, et al. Safety, tolerability, and pharmacokinetics of single oral doses of tofacitinib, a Janus kinase inhibitor, in healthy volunteers. Clin Pharmacol Drug Dev. 2015;4(2):83–88. doi: 10.1002/cpdd.171
   PubMed Web of Science ®Google Scholar
• Xie R, Deng C, Wang Q, et al. Population pharmacokinetics of tofacitinib in patients with psoriatic arthritis. Int J Clin Pharmacol Ther. 2019;57(9):464–473. doi: 10.5414/CP203516
   PubMed Web of Science ®Google Scholar
• Tian F, Chen Z, Xu T. Efficacy and safety of tofacitinib for the treatment of chronic plaque psoriasis: a systematic review and meta-analysis. J Int Med Res. 2019;47(6):2342–2350. doi: 10.1177/0300060519847414
   PubMed Web of Science ®Google Scholar
• Papp KA, Menter A, Strober B, et al. Efficacy and safety of tofacitinib, an oral janus kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo-controlled dose-ranging study: tofacitinib improves the clinical signs of psoriasis. Br J Dermatol. 2012;167(3):668–677. doi: 10.1111/j.1365-2133.2012.11168.x
   PubMed Web of Science ®Google Scholar
• Papp KA, Menter MA, Abe M, et al. Tofacitinib, an oral janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol. 2015;173(4):949–961. doi: 10.1111/bjd.14018
   PubMed Web of Science ®Google Scholar
• Merola JF, Elewski B, Tatulych S, et al. Efficacy of tofacitinib for the treatment of nail psoriasis: two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2017;77(1):79–87.e1. doi: 10.1016/j.jaad.2017.01.053
   PubMed Web of Science ®Google Scholar
• Bachelez H, Van De Kerkhof PCM, Strohal R, et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet. 2015;386(9993):552–561. doi: 10.1016/S0140-6736(14)62113-9
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Iversen L, Sofen H, et al. Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial. Br J Dermatol. 2015;172(5):1395–1406. doi: 10.1111/bjd.13551
   PubMed Web of Science ®Google Scholar
• Mease P, Hall S, FitzGerald O, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017;377(16):1537–1550. doi: 10.1056/NEJMoa1615975
   PubMed Web of Science ®Google Scholar
• Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017;377(16):1525–1536. doi: 10.1056/NEJMoa1615977
   PubMed Web of Science ®Google Scholar
• Nash P, Coates LC, Fleishaker D, et al. Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL balance long-term extension study. Lancet Rheumatol. 2021;3(4):e270–e283. doi: 10.1016/S2665-9913(21)00010-2
   PubMedGoogle Scholar
• Griffiths CEM, Vender R, Sofen H, et al. Effect of tofacitinib withdrawal and re‐treatment on patient‐reported outcomes: results from a phase 3 study in patients with moderate to severe chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):323–332. doi: 10.1111/jdv.13808
   PubMed Web of Science ®Google Scholar
• McInnes IB, Anderson JK, Magrey M, et al. Trial of Upadacitinib and adalimumab for psoriatic arthritis. N Engl J Med. 2021;384(13):1227–1239. doi: 10.1056/NEJMoa2022516
   PubMed Web of Science ®Google Scholar
• Mease PJ, Lertratanakul A, Anderson JK, et al. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis. 2021;80(3):312–320. doi: 10.1136/annrheumdis-2020-218870
   PubMed Web of Science ®Google Scholar
• Burke JR, Cheng L, Gillooly KM, et al. Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain. Sci Transl Med. 2019;11(502):eaaw1736. doi: 10.1126/scitranslmed.aaw1736
   PubMed Web of Science ®Google Scholar
• Nogueira M, Puig L, Torres T. JAK inhibitors for treatment of psoriasis: focus on selective TYK2 inhibitors. Drugs. 2020;80(4):341–352. doi: 10.1007/s40265-020-01261-8
   PubMed Web of Science ®Google Scholar
• Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843–862. doi: 10.1038/nrd.2017.201
   PubMed Web of Science ®Google Scholar
• Krueger JG, McInnes IB, Blauvelt A. Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis. J Am Acad Dermatol. 2022;86:148–157. doi: 10.1016/j.jaad.2021.06.869
   PubMed Web of Science ®Google Scholar
• Shaw MH, Boyartchuk V, Wong S, et al. A natural mutation in the Tyk2 pseudokinase domain underlies altered susceptibility of B10.Q/J mice to infection and autoimmunity. Proc Natl Acad Sci USA. 2003;100(20):11594–11599. doi: 10.1073/pnas.1930781100
   PubMed Web of Science ®Google Scholar
• Lazear HM, Nice TJ, Diamond MS. Interferon-λ: immune functions at barrier surfaces and beyond. Immunity. 2015;43(1):15–28. doi: 10.1016/j.immuni.2015.07.001
   PubMed Web of Science ®Google Scholar
• Catlett IM, Aras U, Hansen L, et al. First‐in‐human study of deucravacitinib: a selective, potent, allosteric inhibitor of tyrosine kinase 2. Clin Transl Sci. 2023;16:151–164. doi: 10.1111/cts.13435
   PubMed Web of Science ®Google Scholar
• Lé AM, Puig L, Torres T. Deucravacitinib for the treatment of psoriatic disease. Am J Clin Dermatol. 2022;23(6):813–822. doi: 10.1007/s40257-022-00720-0
   PubMed Web of Science ®Google Scholar
• Tokarski JS, Zupa-Fernandez A, Tredup JA, et al. Tyrosine Kinase 2-mediated signal transduction in T lymphocytes is blocked by pharmacological stabilization of its pseudokinase domain. J Biol Chem. 2015;290(17):11061–11074. doi: 10.1074/jbc.M114.619502
   PubMed Web of Science ®Google Scholar
• Gillooly K, Zhang Y, Yang X, et al. BMS-986165 is a highly potent and selective Allosteric Inhibitor of Tyk2, blocks IL-12, IL-23 and type I interferon signaling and provides for robust efficacy in preclinical models of systemic lupus erythematosus and inflammatory bowel disease [internet]. ACR Meet. Abstr. [cited 2024 Jan 27]. Available from: https://acrabstracts.org/abstract/bms-986165-is-a-highly-potent-and-selective-allosteric-inhibitor-of-tyk2-blocks-il-12-il-23-and-type-i-interferon-signaling-and-provides-for-robust-efficacy-in-preclinical-models-of-systemic-lupus-e/
   Google Scholar
• Kim LS, Wu JJ, Han G. Deucravacitinib for psoriasis. Curr Dermatol Rep. 2021;10(1):1–5. doi: 10.1007/s13671-020-00326-x
   Web of Science ®Google Scholar
• Hoy SM. Deucravacitinib: first approval. Drugs. 2022;82:1671–1679. doi: 10.1007/s40265-022-01796-y
   PubMedGoogle Scholar
• Bristol Myers Squibb. SOTYKTUTM (deucravacitinib) tablets, for oral use: US prescribing information. 2022. cited 10 Jan 2024. https://packageinserts.bms.com/pi/pi_sotyktu.pdf.
   Google Scholar
• Chimalakonda A, Burke J, Cheng L, et al. Selectivity profile of the tyrosine kinase 2 inhibitor deucravacitinib compared with janus Kinase 1/2/3 inhibitors. Dermatol Ther (Heidelb). 2021;11(5):1763–1776. doi: 10.1007/s13555-021-00596-8
   PubMed Web of Science ®Google Scholar
• Papp K, Gordon K, Thaçi D, et al. Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis. N Engl J Med. 2018;379(14):1313–1321. doi: 10.1056/NEJMoa1806382
   PubMed Web of Science ®Google Scholar
• Mease PJ, Deodhar AA, Van Der Heijde D, et al. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Ann Rheum Dis. 2022;81(6):815–822. doi: 10.1136/annrheumdis-2021-221664
   PubMed Web of Science ®Google Scholar
• Strober B, Thaçi D, Sofen H, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 program for evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol. 2023;88(1):40–51. doi: 10.1016/j.jaad.2022.08.061
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Warren RB, Zhong Y, et al. Short-, mid-, and long-term efficacy of deucravacitinib versus biologics and nonbiologics for plaque psoriasis: a network meta-analysis. Dermatol Ther (Heidelb). 2023;13(11):2839–2857. doi: 10.1007/s13555-023-01034-7
   PubMedGoogle Scholar
• Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017;13(4):234–243. doi: 10.1038/nrrheum.2017.23
   PubMed Web of Science ®Google Scholar
• Zhang L, Guo L, Wang L, et al. The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis – a network meta-analysis. J Eur Acad Dermatol Venereol. 2022;36(11):1937–1946. doi: 10.1111/jdv.18263
   PubMed Web of Science ®Google Scholar
• Chandran V, Siannis F, Rahman P, et al. Folate pathway enzyme gene polymorphisms and the efficacy and toxicity of methotrexate in psoriatic arthritis. J Rheumatol. 2010;37(7):1508–1512. doi: 10.3899/jrheum.091311
   PubMed Web of Science ®Google Scholar
• Vasilopoulos Y, Sarri C, Zafiriou E, et al. A pharmacogenetic study of ABCB1 polymorphisms and cyclosporine treatment response in patients with psoriasis in the Greek population. Pharmacogenomics J. 2014;14(6):523–525. doi: 10.1038/tpj.2014.23
   PubMed Web of Science ®Google Scholar
• Zhou X, He Y, Kuang Y, et al. HLA-DQA1 and DQB1 alleles are associated with acitretin response in patients with psoriasis. Front Biosci-Landmark. 2022;27:266. doi: 10.31083/j.fbl2709266
   PubMed Web of Science ®Google Scholar
• Huang Y-W, Tsai T-F. HLA-Cw1 and psoriasis. Am J Clin Dermatol. 2021;22(3):339–347. doi: 10.1007/s40257-020-00585-1
   PubMed Web of Science ®Google Scholar
• Guarene M, Pasi A, Bolcato V, et al. The presence of HLA-A Bw4-80I KIR ligands could predict “difficult-to-treat” psoriasis and poor response to Etanercept. Mol Diagn Ther. 2018;22:471–474. doi: 10.1007/s40291-018-0345-9
   PubMed Web of Science ®Google Scholar
• Ho S-S, Tsai T-F. Associations between HLA-Cw1 and systemic treatment response of Asian psoriasis patients. Mol Diagn Ther. 2022;26(5):541–549. doi: 10.1007/s40291-022-00603-4
   PubMed Web of Science ®Google Scholar
• West J, Ogston S, Berg J, et al. HLA‐Cw6‐positive patients with psoriasis show improved response to methotrexate treatment. Clin Exp Dermatol. 2017;42(6):651–655. doi: 10.1111/ced.13100
   PubMed Web of Science ®Google Scholar
• van Vugt LJ, van den Reek JMPA, Hannink G, et al. Association of HLA-C*06: 02 status with differential response to Ustekinumab in patients with psoriasis: a systematic review and meta-analysis. JAMA Dermatol. 2019;155:708–715. doi: 10.1001/jamadermatol.2019.0098
   PubMed Web of Science ®Google Scholar
• Li K, Huang CC, Randazzo B, et al. HLA-C*06: 02 allele and response to IL-12/23 inhibition: results from the ustekinumab phase 3 psoriasis program. J Invest Dermatol. 2016;136:2364–2371. doi: 10.1016/j.jid.2016.06.631
   PubMed Web of Science ®Google Scholar
• Temel B, Adisen E, Gonen S. HLA-Cw6 status and treatment responses between psoriasis patients. Indian J Dermatol. 2021;66(6):632–637. doi: 10.4103/ijd.IJD_282_21
   PubMed Web of Science ®Google Scholar
• Chen L, Tsai T-F. HLA-Cw6 and psoriasis. Br J Dermatol. 2018;178(4):854–862. doi: 10.1111/bjd.16083
   PubMed Web of Science ®Google Scholar
• Costanzo A, Bianchi L, Flori ML, et al. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study. Br J Dermatol. 2018;179(5):1072–1080. doi: 10.1111/bjd.16705
   PubMed Web of Science ®Google Scholar
• Shagalov DR, Ferzli GM, Wildman T, et al. Genetic testing in dermatology: a survey analyzing obstacles to appropriate care. Pediatr Dermatol. 2017;34(1):33–38. doi: 10.1111/pde.12981
   PubMed Web of Science ®Google Scholar
• Deverka PA, Kaufman D, McGuire AL. Overcoming the reimbursement barriers for clinical sequencing. JAMA. 2014;312(18):1857–1858. doi: 10.1001/jama.2014.14915
   PubMed Web of Science ®Google Scholar
• Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet Med Off J Am Coll Med Genet. 2015;17:405–424. doi: 10.1038/gim.2015.30
   Google Scholar
• Hermans C, Herranz P, Segaert S, et al. Current practice of therapeutic drug monitoring of biopharmaceuticals in psoriasis patients. Ther Drug Monit. 2017;39(4):356–359. doi: 10.1097/FTD.0000000000000401
   PubMed Web of Science ®Google Scholar
• Gehin JE, Goll GL, Brun MK, et al. Assessing immunogenicity of biologic drugs in inflammatory joint diseases: progress towards personalized medicine. BioDrugs Clin Immunother Biopharm Gene Ther. 2022;36(6):731–748. doi: 10.1007/s40259-022-00559-1
   Google Scholar
• Syversen SW, Goll GL, Jørgensen KK, et al. Effect of therapeutic drug monitoring vs standard therapy during infliximab induction on disease remission in patients with chronic immune-mediated inflammatory diseases: a randomized clinical trial. JAMA. 2021;325(17):1744–1754. doi: 10.1001/jama.2021.4172
   PubMed Web of Science ®Google Scholar
• Elberdín L, Fernández-Torres RM, Mateos M, et al. Real-world use of ustekinumab therapeutic drug monitoring in moderate to severe psoriasis. Front Med. 2022;9:1017323. doi: 10.3389/fmed.2022.1017323
   Web of Science ®Google Scholar
• Sukhpreet TP. Therapeutic drug monitoring of immunosuppressants – an overview. Indian J Pharmacol. 2007;39:66–70. doi: 10.4103/0253-7613.32522
   Web of Science ®Google Scholar
• Carroll CL, Feldman SR, Camacho FT, et al. Better medication adherence results in greater improvement in severity of psoriasis. Br J Dermatol. 2004;151(4):895–897. doi: 10.1111/j.1365-2133.2004.06174.x
   PubMed Web of Science ®Google Scholar
• Thorneloe RJ, Bundy C, Griffiths CEM, et al. Adherence to medication in patients with psoriasis: a systematic literature review. Br J Dermatol. 2013;168(1):20–31. doi: 10.1111/bjd.12039
   PubMed Web of Science ®Google Scholar
• Liau MM, Oon HH. Therapeutic drug monitoring of biologics in psoriasis. Biol Targets Ther. 2019;13:127–132. doi: 10.2147/BTT.S188286
   PubMed Web of Science ®Google Scholar
• Tikhonova I, Yang H, Salmon A, et al. Therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis [internet]. University of Exeter. 2019 [cited 2024 Jan 25]. Available from: https://www.nice.org.uk/guidance/DG36
   Google Scholar
• Krieckaert C, Hernández-Breijo B, Gehin JE, et al. Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider. RMD Open. 2022;8(2):e002216. doi: 10.1136/rmdopen-2022-002216
   PubMed Web of Science ®Google Scholar
• Schots L, Grine L, Soenen R, et al. Dermatologists on the medical need for therapeutic drug monitoring of biologics in psoriasis: results of a structured survey. J Dermatol Treat. 2022;33(3):1473–1481. doi: 10.1080/09546634.2020.1832649
   PubMed Web of Science ®Google Scholar
• Silverman AK, Emmett M, Menter A. Can maintenance cyclosporine be used in psoriasis without decreasing renal function. Semin Dermatol. 1992;11:302–312.
   PubMedGoogle Scholar